(e,e,e,e)-squalene
(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
Cross Reference
Introduction
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with (e,e,e,e)-squalene?
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
PubChem Associated disorders and diseases
What pathways are associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with (e,e,e,e)-squalene?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with (e,e,e,e)-squalene?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with (e,e,e,e)-squalene?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with (e,e,e,e)-squalene
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Rasch MR et al. | Chains, sheets, and droplets: assemblies of hydrophobic gold nanocrystals with saturated phosphatidylcholine lipid and squalene. | 2012 | Langmuir | pmid:23033891 |
| Singh M et al. | MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. | 2012 | Hum Vaccin Immunother | pmid:22832252 |
| Vesikari T et al. | Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. | 2012 | Hum Vaccin Immunother | pmid:22906943 |
| Della Cioppa G et al. | Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults. | 2012 | Hum Vaccin Immunother | pmid:22426371 |
| Ikematsu H et al. | Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. | 2012 | Hum Vaccin Immunother | pmid:22854661 |
| Faenzi E et al. | One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. | 2012 | Vaccine | pmid:22521851 |
| Hatz C et al. | A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. | 2012 | Vaccine | pmid:22626675 |
| Hwang SM et al. | Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. | 2012 | Jpn. J. Infect. Dis. | pmid:22627298 |
| Siegrist CA et al. | Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. | 2012 | Antivir. Ther. (Lond.) | pmid:22544169 |
| Yang M et al. | MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. | 2012 | Int. Immunopharmacol. | pmid:22595192 |
| Cabrera-Vique C et al. | Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. | 2012 | Nutr. Rev. | pmid:22537213 |
| Stella B et al. | Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits. | 2012 | Eur J Pharm Biopharm | pmid:22008147 |
| Nakazawa A et al. | Optimization of culture conditions of the thraustochytrid Aurantiochytrium sp. strain 18W-13a for squalene production. | 2012 | Bioresour. Technol. | pmid:22023965 |
| RamÃrez-Torres A et al. | Proteomics and gene expression analyses of squalene-supplemented mice identify microsomal thioredoxin domain-containing protein 5 changes associated with hepatic steatosis. | 2012 | J Proteomics | pmid:22796066 |
| Surls J et al. | Increased membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory response. | 2012 | PLoS ONE | pmid:22723880 |
| Girod A et al. | Composition of fingermark residue: a qualitative and quantitative review. | 2012 | Forensic Sci. Int. | pmid:22727572 |
| Sarpietro MG et al. | Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. | 2012 | Int J Pharm | pmid:22728161 |
| Wu S et al. | Engineering triterpene metabolism in tobacco. | 2012 | Planta | pmid:22729821 |
| Langley JM et al. | Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. | 2012 | Pediatr. Infect. Dis. J. | pmid:22801094 |
| Block SL et al. | Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. | 2012 | Pediatr. Infect. Dis. J. | pmid:22481427 |
| Sémiramoth N et al. | Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. | 2012 | ACS Nano | pmid:22482704 |
| Langley JM et al. | Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. | 2012 | Vaccine | pmid:22469860 |
| Fukase H et al. | Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. | 2012 | Vaccine | pmid:22472791 |
| Suthiwong J et al. | A new phenolic compound from the stem of Hymenocardia wallichii. | 2012 | J Asian Nat Prod Res | pmid:22423644 |
| Zhang XH et al. | Chemical composition of volatile oils from the pericarps of Indian sandalwood (Santalum album) by different extraction methods. | 2012 | Nat Prod Commun | pmid:22428257 |
| Guzmán Herrador BR et al. | Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. | 2012 | BMC Infect. Dis. | pmid:22429643 |
| Fox CB et al. | Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions. | 2012 | AAPS PharmSciTech | pmid:22415641 |
| Nassim C et al. | Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. | 2012 | Pediatr. Infect. Dis. J. | pmid:22418661 |
| Fox CB et al. | Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. | 2012 | Clin. Vaccine Immunol. | pmid:22896687 |
| Reynales H et al. | A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. | 2012 | Vaccine | pmid:22902681 |
| Desmaële D et al. | Squalenoylation: a generic platform for nanoparticular drug delivery. | 2012 | J Control Release | pmid:21840355 |
| Naziri E et al. | Recovery of squalene from wine lees using ultrasound assisted extraction-a feasibility study. | 2012 | J. Agric. Food Chem. | pmid:22888984 |
| Czajka H et al. | A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. | 2012 | J Prev Med Hyg | pmid:23362618 |
| Dorea JG | Safety of thimerosal in vaccines: for whom and how many doses? | 2011 Mar-Apr | Therapie | pmid:23189333 |
| Kozlov VG and Viktorova EG | [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. | 2011 Mar-Apr | Vopr. Virusol. | pmid:21545042 |
| Durando P et al. | Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. | 2011 Jan-Feb | Hum Vaccin | pmid:21245655 |
| Schellenberger MT et al. | Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. | 2011 Jan-Feb | Hum Vaccin | pmid:21245662 |
| Arguedas A et al. | Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. | 2011 | Hum Vaccin | pmid:21285531 |
| Manuel O et al. | Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. | 2011 | Clin. Infect. Dis. | pmid:21288852 |
| Alghisi F et al. | Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. | 2011 | Thorax | pmid:21228426 |
| Decaro N et al. | Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. | 2011 | Vaccine | pmid:21272607 |
| Niehaus TD et al. | Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. | 2011 | Proc. Natl. Acad. Sci. U.S.A. | pmid:21746901 |
| Fox CB et al. | Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. | 2011 | Vaccine | pmid:21906648 |
| Zuccotti GV et al. | Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. | 2011 | Diabet. Med. | pmid:21916971 |
| Meyer K et al. | A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. | 2011 | PLoS ONE | pmid:21887300 |
| Broeders NE et al. | Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. | 2011 | Clin J Am Soc Nephrol | pmid:21921153 |
| Weyermann C et al. | Initial results on the composition of fingerprints and its evolution as a function of time by GC/MS analysis. | 2011 | J. Forensic Sci. | pmid:20707835 |
| Banzhoff A et al. | Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. | 2011 | Hum Vaccin | pmid:21422814 |
| Parretta E et al. | Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. | 2011 | Vaccine | pmid:21406267 |
| Ambike A et al. | Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. | 2011 | Langmuir | pmid:21413743 |